TFF Pharmaceuticals has leased a plant in Austin, Texas to expand development of its thin film freezing technology, which it says could increase the bioavailability of large molecule drugs. The expansion, of which is self-funded, but no specific financial details have been disclosed, sees TFF lease a 3,500 square-foot research and development plant located in Austin, Texas. “We decided to expand our facilities now to meet the current demand and increased interest in our technology. The TFF business model is…

Naobios has completed the production of a clinical batch of influenza vaccine candidate M2SR, allowing FluGen to begin clinical trials in the US.   FluGen and contract development manufacturing organization (CDMO) Naobios have partnered on the process development of a platform for FluGen’s M2SR vaccine candidate since 2019 and have now reached a key milestone in the collaboration, which will lead to the start of a clinical trial in the US this month.   M2SR is a live, single-replication, supra-seasonal, intranasal flu vaccine.…